<?xml version='1.0' encoding='utf-8'?>
<document id="22538052"><sentence text="Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins." /><sentence text="To support drug development, the drug-drug interaction potential (DDI) of an investigational drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against simvastatin acid, atorvastatin, pravastatin, pitavastatin, fluvastatin, rosuvastatin and estrone 3-sulfate"><entity charOffset="135-160" id="DDI-PubMed.22538052.s2.e0" text="estradiol 17β-glucuronide" /><entity charOffset="180-196" id="DDI-PubMed.22538052.s2.e1" text="simvastatin acid" /><entity charOffset="198-210" id="DDI-PubMed.22538052.s2.e2" text="atorvastatin" /><entity charOffset="212-223" id="DDI-PubMed.22538052.s2.e3" text="pravastatin" /><entity charOffset="225-237" id="DDI-PubMed.22538052.s2.e4" text="pitavastatin" /><entity charOffset="239-250" id="DDI-PubMed.22538052.s2.e5" text="fluvastatin" /><entity charOffset="252-264" id="DDI-PubMed.22538052.s2.e6" text="rosuvastatin" /><entity charOffset="269-286" id="DDI-PubMed.22538052.s2.e7" text="estrone 3-sulfate" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e6" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e0" e2="DDI-PubMed.22538052.s2.e7" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e1" e2="DDI-PubMed.22538052.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e1" e2="DDI-PubMed.22538052.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e1" e2="DDI-PubMed.22538052.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e1" e2="DDI-PubMed.22538052.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e1" e2="DDI-PubMed.22538052.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e1" e2="DDI-PubMed.22538052.s2.e6" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e1" e2="DDI-PubMed.22538052.s2.e7" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e2" e2="DDI-PubMed.22538052.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e2" e2="DDI-PubMed.22538052.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e2" e2="DDI-PubMed.22538052.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e2" e2="DDI-PubMed.22538052.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e2" e2="DDI-PubMed.22538052.s2.e6" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e2" e2="DDI-PubMed.22538052.s2.e7" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e3" e2="DDI-PubMed.22538052.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e3" e2="DDI-PubMed.22538052.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e3" e2="DDI-PubMed.22538052.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e3" e2="DDI-PubMed.22538052.s2.e6" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e3" e2="DDI-PubMed.22538052.s2.e7" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e4" e2="DDI-PubMed.22538052.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e4" e2="DDI-PubMed.22538052.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e4" e2="DDI-PubMed.22538052.s2.e6" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e4" e2="DDI-PubMed.22538052.s2.e7" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e5" e2="DDI-PubMed.22538052.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e5" e2="DDI-PubMed.22538052.s2.e6" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e5" e2="DDI-PubMed.22538052.s2.e7" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e6" e2="DDI-PubMed.22538052.s2.e6" /><pair ddi="false" e1="DDI-PubMed.22538052.s2.e6" e2="DDI-PubMed.22538052.s2.e7" /></sentence><sentence text=" The inhibitory potentials of the OATP1B1 inhibitors rifamycin SV and gemfibrozil were assessed in parallel"><entity charOffset="53-65" id="DDI-PubMed.22538052.s3.e0" text="rifamycin SV" /><entity charOffset="70-81" id="DDI-PubMed.22538052.s3.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.22538052.s3.e0" e2="DDI-PubMed.22538052.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22538052.s3.e0" e2="DDI-PubMed.22538052.s3.e1" /></sentence><sentence text=" Monolayer cellular uptake assays were used to determine inhibition of human OATP1B1" /><sentence text=" Apparent K(m) values for the OATP1B1-mediated transport of [(3)H] substrates were determined prior to their use as probes in inhibition studies, and ranged from 0" /><sentence text="6 to 29 μM for statins" /><sentence text=" The K(m) of lipophilic simvastatin acid could not be determined due to its high passive permeability that masked OATP1B1 transport, and therefore this statin could not be used as a probe"><entity charOffset="24-40" id="DDI-PubMed.22538052.s7.e0" text="simvastatin acid" /></sentence><sentence text=" Estrone 3-sulfate exhibited biphasic kinetics, whereas estradiol 17β-glucuronide demonstrated simple Michaelis-Menton kinetics"><entity charOffset="1-18" id="DDI-PubMed.22538052.s8.e0" text="Estrone 3-sulfate" /></sentence><sentence text=" AZX moderately inhibited OATP1B1-mediated transport of all statins (IC(50)=4" /><sentence text="6-9" /><sentence text="7 μM), except fluvastatin, of estradiol 17β-glucuronide (IC(50)=5"><entity charOffset="14-25" id="DDI-PubMed.22538052.s11.e0" text="fluvastatin" /><entity charOffset="30-55" id="DDI-PubMed.22538052.s11.e1" text="estradiol 17β-glucuronide" /><pair ddi="false" e1="DDI-PubMed.22538052.s11.e0" e2="DDI-PubMed.22538052.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22538052.s11.e0" e2="DDI-PubMed.22538052.s11.e1" /></sentence><sentence text="3 μM), and weakly inhibited estrone 3-sulfate (IC(50)=79 μM)"><entity charOffset="28-45" id="DDI-PubMed.22538052.s12.e0" text="estrone 3-sulfate" /></sentence><sentence text=" Rifamycin SV strongly, and gemfibrozil weakly, inhibited the OATP1B1-mediated transport of substrates"><entity charOffset="1-13" id="DDI-PubMed.22538052.s13.e0" text="Rifamycin SV" /><entity charOffset="28-39" id="DDI-PubMed.22538052.s13.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.22538052.s13.e0" e2="DDI-PubMed.22538052.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22538052.s13.e0" e2="DDI-PubMed.22538052.s13.e1" /></sentence><sentence text=" Estradiol 17β-glucuronide was identified as a good surrogate probe for statins when assessing OATP1B1 inhibitory potential using this test system"><entity charOffset="1-26" id="DDI-PubMed.22538052.s14.e0" text="Estradiol 17β-glucuronide" /></sentence><sentence text=" Inhibition data was used to predict the likelihood of a clinical DDI, using current draft US FDA guidance and recommendations of the International Transporter Consortium" /><sentence text=" Predictions for AZX indicated the potential for an OATP1B1-mediated DDI in vivo and that a clinical interaction study is warranted to confirm whether AZX is an OATP1B1 inhibitor in the clinic" /><sentence text="" /></document>